

Granulomatosis with Polyangiitis (Wegener's) GPA Giant Cell Arteritis GCA

Cryoglobulinemic Vasculitis CV

Cogan's Syndrome CS

Polyarteritis Nodosa PAN

Lupus Vasculitis

Immune Complex SVV

Single Organ Vasculitis



Primary CNS Vasculitis CNS

Microscopic Polyangiitis MPA

Takayasu Arteritis TAK

BEHCET'S Disease BD

Kawasaki Disease KD

Churg Strauss EGPA

Rheumatoid Vasculitis

Sarcoid Vasculitis

Vasculitis Associated with Probable Etiology

Moving Forward Together on Vasculitis

VFC 2016 Fall Lectures - Saturday October 22, 2016

St. Joseph's Healthcare – Charlton Campus

2nd floor Frank Miller Amphitheatre

50 Charlton Avenue East

Hamilton, Ontario

Morning Sessions: Vasculitis Locally, in Canada and Beyond*

**Proposed agenda as of 23.9.15, VFC reserves the right to make program changes as necessary.*

9:00AM – 9:50AM

Registration and Labs for Dr. Siminovitch's ongoing studies

10:00AM – 10:10AM

Welcome and Introductions

O **10:10AM - 10:40AM**

N **Dr. Nader Khalidi, M.D., FRCP(C), FACP, FACR, Associate Professor,**
Department of Medicine & Rheumatology, McMaster University Medical Centre,
Hamilton, ON.

E **Dr. Christian Pagnoux, M.D., M.P.H. Division of Rheumatology,**
Mount Sinai Hospital, Toronto, ON.

Dr. 's Khalidi and Pagnoux will share what's happening in vasculitis both locally and in Canada, as well as cast some insight into the future. Dr. Khalidi will update us on local studies, and those that are recruiting patients, as well as give us a report on current VCRC study numbers. He will also share some cutting edge results using MRI's in GCA and some general thoughts on the changing landscape of GCA. Dr. Pagnoux will give us a more national perspective with an update on CanVasc and how it is moving forward!

T 10:40AM - 11:40AM

**W Dr. Peter Grayson, M.D., M.Sc. National Institute of Arthritis and
O Musculoskeletal and Skin Diseases, (NIAMS), Vasculitis Translational Research
Program Head, Bethesda, MD First time speaker to VF Canada!**

ANCA-associated vasculitis (AAV) and large vessel vasculitis (LVV) are two major forms of vasculitis. Medical advancements in AAV have outpaced progress in LVV. Accordingly, ongoing research initiatives differ between these conditions. Dr. Grayson will discuss why progress in AAV has outpaced efforts in LVV and will review the research needs in these conditions. He will discuss how "big data" can be used to develop personalized medicine approaches in AAV and how cutting-edge imaging technologies can be used to assess vascular inflammation in LVV. As the head of the NIAMS Vasculitis Translational Research Program at the National Institutes of Health, Dr. Grayson will also discuss ongoing research protocols at the NIH for patients with vasculitis.

11:40AM - 12:30PM

Extensive Question and Answer period on all vasculitic diseases.

Vasculitis patients have many, many questions on their individual diseases, such as: which treatment is best for them, what to do about their symptoms and flares, which doctors should they see and how often they should see them, how often to do labs, how can they detect relapses at the earliest stages, how they can get the best possible outcomes, are new clinical trials and treatment options for them, and how can they find the best balance between living with their disease and maintaining the best quality of life?

Don't miss this opportunity to bring your questions, and get advice and answers, from three of the most informed Doctors on everything Vasculitis!

12:30PM – 1:10PM

Lunch Break

For lunch, we suggest ordering a box lunch which you can preorder at the time of your online registration. For \$13 (tax included), your box lunch includes one of three sandwiches (roast beef, turkey, or vegetarian), a bag of chips, an apple, a cookie and one bottle of water.

Please note: there is no "food court" on site. There is a "Tim's" for coffee etc. but it is not full service with sandwiches, soup etc.

Afternoon Sessions: Continuing to Move Forward on Vasculitis *

**Proposed agenda as of 23.9.15, VFC reserves the right to make program changes as necessary.*

1:10PM – 1:20PM

Afternoon Introduction

T **1:20PM – 1:50PM** *(This presentation includes about 10 minutes for Q&A)*

H **Dr. Katherine Siminovitch, M.D., FRCP(C),** Professor of Medicine,
R Rheumatologist, Geneticist, Senior Investigator at the Samuel Lunenfeld Research
R Institute of Mount Sinai Hospital, Toronto, ON.

E *Dr. Siminovitch, will explain why she continues to collect all those fresh blood*
E *cell samples, at regular intervals, and its impact on her work this past spring and*
summer. With more than 15 years of data she has learned a lot, and gone from
nowhere to somewhere! What was once just unlocking the genetics of
GPA/MPA she is now focusing on unlocking the role of the proteins at play in
the overall genetic picture. It is hoped this will lead to earlier, more accurate,
diagnostic testing with much better and targeted/individualized treatments. Of
course, it is hoped that what is learned in GPA, and now MPA, will translate into
important insights into the broader vasculitis family.

F **1:50PM – 2:20PM**

O **Dr. Gerard Cox, MB, Bch, FRCP(C), FRCP(I)**
U Professor Department of Medicine, Chair, McMaster University
R Co-ordinator of Regional Clinical Services, Division of Respiratory,
First time speaker to VF Canada!

Even after the diagnosis of lung involvement in ANCA Associated Vasculitis (AAV), the lung can present many challenges, not the least of which can be figuring out where the problem is, and whether new symptoms are caused by the disease, medications or something else. Even in well maintained chronic disease, how does one diagnosis new lung manifestations? They can be something acute, drug induced, disease relapse or something new like, for example, interstitial lung disease. Dr. Cox will review the initial problem then look forward to some of the complications, and solutions, that can follow after diagnosis, including new and emerging concerns previously not encountered.

F 2:20PM – 2:50PM

Dr. Michael Walsh, M.D., PhD.

I Assistant Professor of Medicine (Nephrology), Clinical Epidemiology and
V Biostatistics, Population Health Research Institute, McMaster University,
E Hamilton, Ontario

Treatments for ANCA associated vasculitis have come a long way over the last 50 years but they still have a long way to go. Research is the key to developing better ways of treating vasculitis. Dr. Walsh will review why we need clinical trials and update us on PEXIVAS, the largest clinical trial in vasculitis, which is wrapping-up in the Fall of 2017. Finally, he'll gaze into the crystal ball and give us some insight into the next five years of clinical trial research in vasculitis.

2:50AM - 3:20PM

Afternoon Question and Answer period on all vasculitic diseases

3:20PM – 3:30PM

Afternoon Session - Wrap-up and Good Bye

Symposium Registration is FREE for VF Canada members, (whose memberships are current!), non-members can attend by making a \$20 donation, or by becoming a member with a \$20 Canadian membership, or a dual Canada/U.S. membership for \$55. Lunch is not included and must be preordered at time of registration, space may be limited so register early!

Mark your Calendars! Tentative 2017 Meeting Dates			
AGM - April 22	Walk/Picnic - June 24	BriStrength - July 9	Fall Meeting - Oct. 21

Follow us on Facebook & Twitter! www.facebook.com/Vasc.Canada
www.twitter.com/@Vasculitis_CND

*** Vasculitis Foundation Canada * Foundation Vasculites Canada ***

Suite 446, 425 Hespeler Road, Cambridge, Ontario N1R 8J6
1 877 572-9474 * contact@vasculits.ca * www.vasculitis.ca

Care  Control  Cause  Cure